» Articles » PMID: 35132265

Long-term Cardiovascular Outcomes of COVID-19

Overview
Journal Nat Med
Date 2022 Feb 8
PMID 35132265
Authors
Affiliations
Soon will be listed here.
Abstract

The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized. Here we used national healthcare databases from the US Department of Veterans Affairs to build a cohort of 153,760 individuals with COVID-19, as well as two sets of control cohorts with 5,637,647 (contemporary controls) and 5,859,411 (historical controls) individuals, to estimate risks and 1-year burdens of a set of pre-specified incident cardiovascular outcomes. We show that, beyond the first 30 d after infection, individuals with COVID-19 are at increased risk of incident cardiovascular disease spanning several categories, including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure and thromboembolic disease. These risks and burdens were evident even among individuals who were not hospitalized during the acute phase of the infection and increased in a graded fashion according to the care setting during the acute phase (non-hospitalized, hospitalized and admitted to intensive care). Our results provide evidence that the risk and 1-year burden of cardiovascular disease in survivors of acute COVID-19 are substantial. Care pathways of those surviving the acute episode of COVID-19 should include attention to cardiovascular health and disease.

Citing Articles

Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.

Sun D, Lien T, Chang H Int J Mol Sci. 2025; 26(5).

PMID: 40076527 PMC: 11899886. DOI: 10.3390/ijms26051898.


NETosis: A key player in autoimmunity, COVID-19, and long COVID.

Monsalve D, Acosta-Ampudia Y, Acosta N, Celis-Andrade M, Sahin A, Yilmaz A J Transl Autoimmun. 2025; 10:100280.

PMID: 40071133 PMC: 11894324. DOI: 10.1016/j.jtauto.2025.100280.


Coronavirus Disease 2019 Case Series in China: Sequelae and Effectiveness of Vaccination and Antiviral Drugs.

Ren M Infect Drug Resist. 2025; 18:1125-1133.

PMID: 40027918 PMC: 11871847. DOI: 10.2147/IDR.S499058.


Exploring in-hospital clinical outcomes among acute myocardial infarction patients with prior COVID-19 history.

Sharma K, Patel I, Parikh R, Kalyani M, Banker K, Dhorajiya D J Cardiovasc Thorac Res. 2025; 16(4):275-280.

PMID: 40027369 PMC: 11866775. DOI: 10.34172/jcvtr.33107.


Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.

Naiditch H, Betts M, Larman H, Levi M, Rosenberg A Front Immunol. 2025; 15:1376654.

PMID: 40012912 PMC: 11861071. DOI: 10.3389/fimmu.2024.1376654.


References
1.
Song W, FitzGerald G . COVID-19, microangiopathy, hemostatic activation, and complement. J Clin Invest. 2020; 130(8):3950-3953. PMC: 7410042. DOI: 10.1172/JCI140183. View